Follow
Jessie Au
Jessie Au
Optimum Therapeutics, LLC
Verified email at optimumtx.com
Title
Cited by
Cited by
Year
Comprehensive molecular characterization of urothelial bladder carcinoma
Cancer Genome Atlas Research Network
Nature 507 (7492), 315, 2014
25802014
Delivery of siRNA therapeutics: barriers and carriers
J Wang, Z Lu, MG Wientjes, JLS Au
The AAPS journal 12, 492-503, 2010
8842010
Drug delivery and transport to solid tumors
SH Jang, MG Wientjes, D Lu, JLS Au
Pharmaceutical research 20, 1337-1350, 2003
6382003
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer
G Hu, RA Chong, Q Yang, Y Wei, MA Blanco, F Li, M Reiss, JLS Au, ...
Cancer cell 15 (1), 9-20, 2009
5092009
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses
L Zhao, MG Wientjes, JLS Au
Clinical cancer research 10 (23), 7994-8004, 2004
4612004
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial
JLS Au, RA Badalament, MG Wientjes, DC Young, JA Warner, ...
Journal of the National Cancer Institute 93 (8), 597-604, 2001
4132001
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial
JLS Au, RA Badalament, MG Wientjes, DC Young, JA Warner, ...
Journal of the National Cancer Institute 93 (8), 597-604, 2001
4132001
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial
JLS Au, RA Badalament, MG Wientjes, DC Young, JA Warner, ...
Journal of the National Cancer Institute 93 (8), 597-604, 2001
4122001
Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy
Z Lu, TK Yeh, M Tsai, JLS Au, MG Wientjes
Clinical Cancer Research 10 (22), 7677-7684, 2004
3212004
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs
SH Song, MG Wientjes, Y Gan, JLS Au
Proceedings of the National Academy of Sciences 97 (15), 8658-8663, 2000
2622000
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor
Y Li, J Wang, MG Wientjes, JLS Au
Advanced drug delivery reviews 64 (1), 29-39, 2012
2482012
Comparison of methods for evaluating drug-drug interaction
L Zhao, JLS Au, MG Wientjes
Frontiers in bioscience (Elite edition) 2, 241, 2010
2172010
The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies
VC Ramani, A Purushothaman, MD Stewart, CA Thompson, I Vlodavsky, ...
The FEBS journal 280 (10), 2294-2306, 2013
2132013
Determinants of drug delivery and transport to solid tumors
JLS Au, SH Jang, J Zheng, CT Chen, S Song, L Hu, MG Wientjes
Journal of controlled release 74 (1-3), 31-46, 2001
2122001
Intravesical treatments of bladder cancer
Z Shen, T Shen, MG Wientjes, MA O’Donnell, JLS Au
Pharmaceutical research 25, 1500-1510, 2008
2082008
Determinants of paclitaxel penetration and accumulation in human solid tumor
HJ Kuh, SH Jang, MG Wientjes, JR Weaver, JLS Au
Journal of Pharmacology and Experimental Therapeutics 290 (2), 871-880, 1999
2071999
Intraperitoneal therapy for peritoneal cancer
Z Lu, J Wang, MG Wientjes, JLS Au
Future oncology 6 (10), 1625-1641, 2010
1862010
Kinetics of P-glycoprotein-mediated efflux of paclitaxel
SH Jang, MG Wientjes, JLS Au
Journal of Pharmacology and Experimental Therapeutics 298 (3), 1236-1242, 2001
1602001
Tumor priming enhances delivery and efficacy of nanomedicines
D Lu, MG Wientjes, Z Lu, JLS Au
Journal of Pharmacology and Experimental Therapeutics 322 (1), 80-88, 2007
1532007
Protection against chemotherapy-induced alopecia
J Wang, Z Lu, JLS Au
Pharmaceutical research 23, 2505-2514, 2006
1532006
The system can't perform the operation now. Try again later.
Articles 1–20